Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > The search for vaccines will never stop now

<< Previous

Bullboard Posts

Next >>

Comment by threefiftynineon Jul 07, 2020 9:55am

72 Views

Post# 31233091

RE:The search for vaccines will never stop now

excellent post kevlin139 ---as good as it gets and 100% correct---my "getting left behind" was the wrong choice of wording ----the PP amount sold and insiders participating is prime now going forward and will tell the whole story---hold your breath and hope for the best

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue